FDA Import Alert Flags Two Chinese GLP-1 Ingredient Manufacturers: What COAs Cannot Prove

Updated October 19, 2026. Two Chinese pharmaceutical manufacturers were added to an FDA import alert covering foreign firms that have not met drug current good manufacturing practice (CGMP) requirements. The findings are relevant to anyone evaluating peptide supply-chain claims—but they do not establish that any particular research vendor uses these manufacturers.

What FDA records confirm

FDA’s Import Alert 66-40, titled Detention Without Physical Examination of Drugs From Firms Which Have Not Met Drug GMPs, lists Chengdu Shengnuo Biopharm Co., Ltd. with a September 19, 2026 date and Nanjing Chengong Pharmaceutical Co., Ltd. with an October 1, 2026 date. The alert allows FDA personnel to detain covered shipments without physical examination. This is an import-control action, not proof that every product made by the listed firms was contaminated.

What investigators reportedly found

October 15 reporting, citing FDA inspection documents obtained by journalists, described contamination and records-handling concerns at Chengdu Shengnuo, including reports of insects and mold. Reporting about Nanjing Chengong described concerns about approval of ingredients obtained from other sources without adequate verification of the underlying records. These details come from published accounts of inspection records; they should not be presented as independently tested findings about finished products sold by any PepDiscounts-listed vendor.

Why a peptide COA does not settle the sourcing question

A third-party certificate of analysis can support a claim about a particular submitted sample and tested parameters. It does not by itself establish the manufacturing facility, supplier chain, storage conditions or CGMP compliance. A vendor claiming eight tests per batch still needs verifiable batch identifiers and authentic lab records.

A practical vendor-verification checklist

• Ask whether the vendor can identify the actual manufacturer or origin of each lot.
• Match lot identifiers on the COA to the offered inventory.
• Confirm the report directly with the testing laboratory where possible.
• Check the test methods and whether the COA addresses identity, purity or other specific parameters.
• Do not assume that a COA establishes sterile manufacture, regulatory approval or fitness for human use.

What this means for PepDiscounts vendor listings

PepDiscounts will distinguish vendor-disclosed testing and sourcing information from independently verified evidence. A manufacturer appearing on an FDA import alert is a reason to investigate relevant supply chains, not a basis to accuse unrelated vendors of misconduct. Read our guide to reading peptide COAs and research vendor directory.

Sources

• FDA Import Alert 66-40 (primary source)
• October 15 reporting on inspection findings

For research information only. No inference is made about the supply chain of any individual PepDiscounts-listed vendor.